Issue 9, 2014

Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery

Abstract

Since the launch of Gleevec in 2001, several protein kinases have emerged as attractive therapeutic targets for the treatment of various cancers. One of these, anaplastic lymphoma kinase (ALK), has attracted a great deal of attention due to its oncogenic potential and essential role in the pathogenesis of a wide variety of human cancers, such as ALCLs, NSCLC, breast cancer, colorectal cancer, neuroblastoma, ovarian cancer, etc. To date, nine ALK inhibitors have entered clinical investigation for the treatment of cancers, including crizotinib, the first ALK inhibitor to be approved by the US FDA (in 2011) for the treatment of NSCLC patients. As resistance to crizotinib treatment has been reported in both preclinical and clinical settings, several second-generation ALK inhibitors to overcome both the wild-type and mutant ALK are being developed. In 2014, shortly after crizotinib was approved, the second-generation ALK inhibitor ceritinib was approved by the FDA. Biological activities of eight second-generation clinical ALK inhibitors are discussed in this review. Furthermore, the hit-to-drug evolution strategies used in the design of three ALK inhibitors – crizotinib, alectinib and ceritinib – are described in detail, to help medicinal chemists to understand and devise similar strategies to overcome lead development issues, such as potency, selectivity and metabolism, in the drug discovery projects.

Graphical abstract: Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery

Article information

Article type
Review Article
Submitted
07 Feb 2014
Accepted
09 Jun 2014
First published
21 Jul 2014

Med. Chem. Commun., 2014,5, 1266-1279

Author version available

Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery

W. Wang, H. Shiao, C. Lee, K. Fung and H. Hsieh, Med. Chem. Commun., 2014, 5, 1266 DOI: 10.1039/C4MD00048J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements